PIONEER REAL Spain : A multicentre, prospective, real‐world study of oral semaglutide use in adults with type 2 diabetes
Diabetes, Obesity and Metabolism · 2025
DOI: 10.1111/dom.16523 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Diabetes, Obesity and Metabolism, 2025. Verfasst von Elías Delgado Álvarez und 10 weiteren Autor:innen. Beteiligte Einrichtung: Hospital Universitario Central de Asturias, Universidad de Oviedo, Instituto de Investigación Sanitaria del Principado de Asturias, Oviedo, Spain. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Glucagon-Like Peptide-1 Receptor Agonists. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Novo Nordisk A/S.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Aims This study evaluated clinical outcomes of oral semaglutide treatment in adults with type 2 diabetes (T2D) in a real‐world setting in Spain as part of the 13‐country PIONEER REAL programme. Materials and Methods This multicentre, prospective, non‐interventional, single‐arm study (NCT05443334) followed participants for 34–44 weeks. Participants were treated as part of routine clinical practice and were naïve to injectable glucose‐lowering medication. The primary endpoint was the change in glycated haemoglobin (HbA 1c ) from baseline to end of study (EOS). Secondary endpoints included changes in body weight, the proportion of participants with HbA 1c 5 years. At EOS, 77.4% of participants achieved an HbA 1c level
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hospital Universitario Central de Asturias, Universidad de Oviedo, Instituto de Investigación Sanitaria del Principado de Asturias, Oviedo, Spain.
- Centro de Investigación Biomédica en Red Enfermedades Raras (CIBERER), Madrid, Spain.
- Hospital Vithas Sevilla, Servicio de Endocrinología, Sevilla, Spain.
- Complejo Asistencial de Segovia, Servicio de Endocrinología, Segovia, Spain.
- Clínica Nuevas Tecnologías en Diabetes y Endocrinología, Sevilla, Spain.
- Naranco Health Center, Public Health Service of the Principality of Asturias (SESPA), Oviedo, Spain.
ORCID-Profile: Elías Delgado Álvarez, Cristóbal Morales Portillo, Cristina Abreu Padín, Alberto Aliaga Verdugo, Ana Piera Carbonell, Aída Cadenas González, Jaime Amor Valero, Christina Louise Rasmussen, Stine Hedegaard Scheuer, Diego Bellido Guerrero
Förderung
- Novo Nordisk A/S
Zitieren
APA
Delgado Álvarez, E., Morales Portillo, C., Abreu Padín, C., Aliaga Verdugo, A., Piera Carbonell, A., Cadenas González, A., Amor Valero, J., González López, V., Rasmussen, C. L., Scheuer, S. H., & Bellido Guerrero, D. (2025). PIONEER REAL Spain : A multicentre, prospective, real‐world study of oral semaglutide use in adults with type 2 diabetes. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.16523
Vancouver
Delgado Álvarez E, Morales Portillo C, Abreu Padín C, Aliaga Verdugo A, Piera Carbonell A, Cadenas González A, et al. PIONEER REAL Spain : A multicentre, prospective, real‐world study of oral semaglutide use in adults with type 2 diabetes. Diabetes, Obesity and Metabolism. 2025. doi:10.1111/dom.16523
BibTeX
@article{Delgadolvarez2025,
author = {Delgado Álvarez, Elías and Morales Portillo, Cristóbal and Abreu Padín, Cristina and Aliaga Verdugo, Alberto and Piera Carbonell, Ana and Cadenas González, Aída and Amor Valero, Jaime and González López, Verónica and Rasmussen, Christina Louise and Scheuer, Stine Hedegaard and Bellido Guerrero, Diego},
title = {PIONEER REAL Spain : A multicentre, prospective, real‐world study of oral semaglutide use in adults with type 2 diabetes},
journal = {Diabetes, Obesity and Metabolism},
year = {2025},
doi = {10.1111/dom.16523}
}
EUVIMED